Candidiasis of lung
ICD-10 B37.4 is a billable code used to indicate a diagnosis of candidiasis of lung.
Candidiasis of the lung, also known as pulmonary candidiasis, is a rare but serious fungal infection primarily caused by the Candida species, most commonly Candida albicans. This condition typically occurs in immunocompromised patients, including those with HIV/AIDS, cancer, or those undergoing immunosuppressive therapy. The infection can manifest as a result of inhalation of airborne spores or through hematogenous spread from other infected sites. Clinically, patients may present with symptoms such as cough, fever, chest pain, and difficulty breathing. Diagnosis is often confirmed through imaging studies, such as chest X-rays or CT scans, and microbiological cultures of respiratory secretions. Treatment usually involves antifungal medications, with fluconazole and amphotericin B being the most commonly used agents. Early diagnosis and appropriate antifungal therapy are crucial for improving outcomes in affected patients, particularly those with weakened immune systems.
Detailed clinical notes on respiratory symptoms, imaging results, and treatment plans.
Patients presenting with respiratory distress and a history of immunosuppression.
Ensure that all relevant diagnostic tests are documented to support the diagnosis.
Comprehensive history of the patient's immune status and previous infections.
Patients with recurrent infections or those undergoing treatment for malignancies.
Documentation should include the rationale for antifungal therapy and any resistance patterns.
When lung biopsy is performed to confirm candidiasis.
Pathology report must indicate the presence of Candida species.
Pulmonologists and pathologists must collaborate on documentation.
Common symptoms include cough, fever, chest pain, and difficulty breathing, particularly in immunocompromised patients.
Diagnosis typically involves imaging studies, microbiological cultures, and clinical evaluation of symptoms.
Common antifungal treatments include fluconazole and amphotericin B, depending on the severity of the infection and the patient's overall health.
